Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -1.04 | $0 | -$3M |
| 2025 Q4 | -1.41 | $0 | -$3M |
| 2025 Q3 | -1.31 | $0 | -$2M |
| 2025 Q2 | -1.87 | $0 | -$3M |
| 2025 Q1 | -2.09 | $0 | -$5M |
| 2024 Q4 | -2.75 | $0 | -$2M |
| 2024 Q3 |
| -2.18 |
| $0 |
| -$2M |
| 2024 Q2 | -2.24 | $0 | -$2M |